Neumora Therapeutics, Inc. Common Stock (NMRA) compared with its closest peers (IPSC, PALI, STRO, AGEN, IKT). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $373.92M | -7.0 |
| Palisade Bio, Inc. (PALI) | $367.71M | -7.9 |
| Sutro Biopharma, Inc. (STRO) | $347.32M | -0.5 |
| Agenus Inc. (AGEN) | $336.68M | 2.4 |
| Inhibikase Therapeutics, Inc. (IKT) | $333.49M | -4.2 |
| Anavex Life Sciences Corp. (AVXL) | $296.55M | -16.5 |
| SAB Biotherapeutics, Inc. (SABS) | $288.27M | -4.7 |
| Surrozen, Inc. (SRZN) | $278.18M | -0.7 |
| Fate Therapeutics, Inc. (FATE) | $277.98M | -0.9 |
| Lineage Cell Therapeutics, Inc. (LCTX) | $273.14M | -6.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NMRA overview · NMRA earnings · NMRA financials · NMRA KPIs · NMRA investor relations · NMRA ownership · NMRA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.